Search
Recursion Pharmaceuticals Inc
RXRXAdd to Watchlist
3.630USD
+0.190+5.52%
Close 09-04 16:00（ET）
1.94BMarket Cap
LossP/E TTM
Forecast
Currency: USD Updated: 2026-09-04The current earnings forecast score of Recursion Pharmaceuticals Inc is 6.86, ranking 307 out of 368 in the Biotechnology & Medical Research industry. The average price target is 6.00, with a high of 10.00 and a low of 3.00.
Analyst Rating
Based on
7
analysts
Hold
Current Rating
6.660
Target Price
+100.00%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
497
Total
6
Median
7
Average
Company name
Ratings
Analysts
Recursion Pharmaceuticals Inc
RXRX
7
argenx SE
ARGX
28
Beigene Ltd
ONC
28
IQVIA Holdings Inc
IQV
25
Ionis Pharmaceuticals Inc
IONS
25
Kymera Therapeutics Inc
KYMR
23
1
2
3
...
100
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Recursion Pharmaceuticals Inc's expected revenue for the next quarter?
Recursion Pharmaceuticals Inc's expected revenue is 14.19M.
What is Recursion Pharmaceuticals Inc's price target?
Analysts forecast that Recursion Pharmaceuticals Inc's price target is USD 6.00, with the highest forecast at USD 10.00 and the lowest forecast at USD 3.00.
How have Recursion Pharmaceuticals IncRXRX's recent earnings per share performed?
The market expectation was USD -0.25, while Recursion Pharmaceuticals IncRXRX's earnings per share (EPS) for the previous quarter was USD -0.22. EPS for the next quarter is expected at USD -0.23.
What is the analyst rating for Recursion Pharmaceuticals Inc?
Based on the ratings of Recursion Pharmaceuticals Inc's stock from 7 analysts, most analysts support a signal_hold trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as signal_hold. Please note that this is not trading advice. You still need to conduct your own analysis.